Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.66 |
| ▸ | NQO1 | P15559 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553013 | 1.00 | SLC6A4 (0.66) | SLC6A4NQO1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL256094 | 0.94 | SLC6A4 (0.59) | SLC6A4NQO1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL163358 | 0.91 | ACACB (0.60) | SLC6A4 | |
| Hydrochloric Acid SCHEMBL164344 | 0.90 | ACACB (0.59) | — | |
| SCHEMBL10084809 | 0.85 | SLC6A4 (0.61) | SLC6A4TAAR1MAOA | |
| SCHEMBL10562624 | 0.84 | SLC6A4 (0.56) | SLC6A4TAAR1SLC6A2SLC6A3MAOA | |
| SCHEMBL5018760 | 0.83 | NQO1 (0.61) | NQO1 | |
| SCHEMBL10774512 | 0.82 | SLC6A4 (0.63) | SLC6A4TAAR1SLC6A2SLC6A3MAOA | |
| SCHEMBL17045244 | 0.82 | NQO1 (0.54) | SLC6A4NQO1 | |
| SCHEMBL17045265 | 0.82 | NQO1 (0.54) | SLC6A4NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4358943-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | disclosed |
| CN-117715632-A | Compositions comprising an enzyme-cleavable prodrug and nafamostat and methods of use thereof | 恩赛斯生物科学股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2022269264-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | disclosed |
| US-20220287992-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | 3I, LP | 2022-09-15 | — | — | US | disclosed |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2020-08-13 | — | — | US | disclosed |
| US-20160235694-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2016-08-18 | — | — | US | disclosed |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2560486-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2012122412-A2 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133347-A1 | COMPOSITIONS COMPRISING TRYPSIN-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | SLC6A4 352/4885NQO1 1414/4885TAAR1 238/4885 |
| US-20160235694-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | SLC6A4 352/4885NQO1 1414/4885TAAR1 238/4885 |
| US-20220287992-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | DNPEP, PEPD, CEL | SLC6A4 1971/4885NQO1 700/4885TAAR1 2755/4885 |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | CYP2C19, CYP3A5, CYP3A4 | SLC6A4 580/4885NQO1 840/4885TAAR1 1084/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | SLC6A4 1599/4885NQO1 820/4885TAAR1 543/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | SLC6A4 3378/4885NQO1 3625/4885TAAR1 4008/4885 |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | SLC6A4 352/4885NQO1 1414/4885TAAR1 238/4885 |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | SLC6A4 352/4885NQO1 1414/4885TAAR1 238/4885 |
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | SLC6A4 352/4885NQO1 1414/4885TAAR1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.